Evidence map›Paper›PMID 41992832›Full record

ArticleThe oncologist2026

Comparative real-world progression free survival of CDK4/6 inhibitors in HR+/HER2- breast cancer patients with bone metastases.

Roberta Scafetta, Marco Donato, Carla Gullotta, Alessandra Guarino, Cristina Fiore, Luisana Sisca, Elena Speziale, Raffaella Troiano, Simone Foderaro, Fabio Venuti and 68 more

Abstract readMulticenter StudyComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

78 authors.

Roberta ScafettaMedical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico Via Alvaro del Portillo 200, Italy.
Marco DonatoDivision of Medical Oncology, "G.Martino" University Hospital, Via Consolare Valeria 1, 98124, Messina, Italy.
Carla GullottaMedical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico Via Alvaro del Portillo 200, Italy.
Alessandra GuarinoMedical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico Via Alvaro del Portillo 200, Italy.
Cristina FioreMedical Oncology Unit, Santa Rosa Hospital, Department of Oncology and Hematology, Strada Sammartinese snc, 01100 Viterbo, Italy.
Luisana SiscaMedical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico Via Alvaro del Portillo 200, Italy.
Elena SpezialeMedical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico Via Alvaro del Portillo 200, Italy.
Raffaella TroianoMedical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico Via Alvaro del Portillo 200, Italy.
Simone FoderaroDepartment of Medicine and Surgery, Università Campus Bio-Medico di Roma, Via Alvaro del Portillo 21, 00128, Roma, Italy.
Fabio VenutiMedical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico Via Alvaro del Portillo 200, Italy.
Francesco Antonio VilardiMedical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico Via Alvaro del Portillo 200, Italy.
Valentina RicozziDepartment of Medicine and Surgery, Università Campus Bio-Medico di Roma, Via Alvaro del Portillo 21, 00128, Roma, Italy.
Michele IulianiMedical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico Via Alvaro del Portillo 200, Italy.
Sonia SimonettiMedical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico Via Alvaro del Portillo 200, Italy.ORCID 0000-0002-0673-1272
Silvia CavaliereMedical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico Via Alvaro del Portillo 200, Italy.
Alessio CortelliniMedical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico Via Alvaro del Portillo 200, Italy.
Annalisa La CesaMedical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico Via Alvaro del Portillo 200, Italy.
Andrea BotticelliDepartment of Radiological, Oncological and Pathological Science, "Sapienza" University of Rome, Rome, Italy.ORCID 0000-0002-6425-9893
Simone ScagnoliDepartment of Radiological, Oncological and Pathological Science, "Sapienza" University of Rome, Rome, Italy.ORCID 0000-0003-4943-5622
Simona PisegnaDepartment of Experimental Medicine, Sapienza University, Rome, Italy.ORCID 0000-0002-6910-9528
Carmen CriscitielloDepartment of Oncology and Hemato-Oncology, University of Milan, Milano, Italy.ORCID 0000-0001-9064-0113
Alessandra ChircoASST Papa Giovanni XXIII-SC Oncologia, 24127 Bergamo, Italy.
Sara D'AlessandroASST Papa Giovanni XXIII-SC Oncologia, 24127 Bergamo, Italy.
Rebecca PedersiniMedical Oncology Department, ASST Spedali Civili of Brescia, Brescia, Italy.
Caterina SposettiDepartment of Oncology and Hemato-Oncology, University of Milan, Milano, Italy.
Elisa TiberiDepartment of Medical Oncology, Università Politecnica Delle Marche, AOU delle Marche, Ancona, Italy.
Giuliana D'AuriaDepartment of Medical Oncology, Medical Oncology Unit, Sandro Pertini Hospital, Rome, Italy.
Matteo VergatiDepartment of Medical Oncology, Medical Oncology Unit, Sandro Pertini Hospital, Rome, Italy.
Marco MazzottaDepartment of Medical Oncology, Medical Oncology Unit, Sandro Pertini Hospital, Rome, Italy.
Roberta CaputoDepartment of Breast and Thoracic Oncology, Division of Breast Medical Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Pascale, Naples, Italy.ORCID 0000-0003-4231-1184
Annarita VerrazzoDepartment of Breast and Thoracic Oncology, Division of Breast Medical Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Pascale, Naples, Italy.
Maria Grazia RossinoMedical Oncology Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122, Milan, Italy.
Federica DomatiDepartment of Oncology and Hematology, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
Claudia PiombinoDepartment of Oncology and Hematology, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
Francesca Sofia Di LisaUOSD Sperimentazioni di fase IV-IRCCS Istituto Nazionale Tumori Regina Elena, Via Elio Chianesi, Italia.
Lorena FilomenoUOSD Sperimentazioni di fase IV-IRCCS Istituto Nazionale Tumori Regina Elena, Via Elio Chianesi, Italia.
Teresa ArcuriUOSD Sperimentazioni di fase IV-IRCCS Istituto Nazionale Tumori Regina Elena, Via Elio Chianesi, Italia.
Federica PuceMedical Oncology Unit, ICS Maugeri IRCCS, Pavia, Italy.
Federica RivaDepartment of Clinical and Molecular Medicine, "La Sapienza" University of Rome Policlinico Umberto I, Viale Regina Elena 324, Italy.
Michela PalleschiMedical Oncology, Breast & GYN Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
Marianna SiricoMedical Oncology, Breast & GYN Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
Marta PirasDepartment of Medical Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Luigia Stefania StucciInterdisciplinary Department of Medicine, University of Bari "A. Moro" and Division of Medical Oncology, A.O.U. Consorziale Policlinico di Bari, Bari, Italy.
Delia De LisiMedical Oncology Unit, Santa Chiara Hospital, APSS Trento, Italy.
Paolo OrsariaDepartment of Breast Surgery, Fondazione Policlinico Universitario Campus Bio-Medico, Rome,  Italy.
Antonella GrassoDepartment of Breast Surgery, Fondazione Policlinico Universitario Campus Bio-Medico, Rome,  Italy.
Edy IppolitoDepartment of Radiation Oncology (Medicine and Surgery), Università Campus Bio-Medico di Roma, Rome, Italy.
Sara RamellaDepartment of Radiation Oncology (Medicine and Surgery), Università Campus Bio-Medico di Roma, Rome, Italy.
Luca VisaniRadiation Oncology Unit & Breast Unit, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.
Niccolò BertiniMedical Oncology, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar di Valpolicella (VR), Italy.
Ilaria BonaparteRadiation Oncology Unit & Breast Unit, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.
Stefania GoriMedical Oncology, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar di Valpolicella (VR), Italy.ORCID 0000-0001-6320-405X
Luigi RossiUOC of Oncology - ASL Latina - Distretto 1, University of Rome "Sapienza", Formia, Italy.
Icro MeattiniRadiation Oncology Unit & Breast Unit, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.ORCID 0000-0002-1861-2895
Barbara TagliaferriMedical Oncology Unit, ICS Maugeri IRCCS, Pavia, Italy.
Orazio CaffoMedical Oncology Unit, Santa Chiara Hospital, APSS Trento, Italy.
Maria Vittoria BonomoMedical Oncology Unit, Policlinico Universitario Tor Vergata, Italy.
Ilaria PortarenaMedical Oncology Unit, Policlinico Universitario Tor Vergata, Italy.
Azzurra IrelliMedical Oncology Unit, Department of Oncology, "Giuseppe Mazzini" Hospital, AUSL 04 Teramo, 64100 Teramo, Italy.
Elisabetta CretellaMedical Oncology Unit, Ospedale di Bolzano, Bolzano, Italia.
Camillo PortaInterdisciplinary Department of Medicine, University of Bari "A. Moro" and Division of Medical Oncology, A.O.U. Consorziale Policlinico di Bari, Bari, Italy.
Giampaolo BianchiniDepartment of Medical Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy.ORCID 0000-0002-6790-6267
Maria Agnese FabbriMedical Oncology Unit, Santa Rosa Hospital, Department of Oncology and Hematology, Strada Sammartinese snc, 01100 Viterbo, Italy.
Ugo De GiorgiDepartment of Experimental Medicine, University of Salento, Lecce, Italy.ORCID 0000-0001-7520-2908
Patrizia ViciUOSD Sperimentazioni di fase IV-IRCCS Istituto Nazionale Tumori Regina Elena, Via Elio Chianesi, Italia.
Angela TossDepartment of Oncology and Hematology, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.ORCID 0000-0002-1854-6701
Ornella GarroneMedical Oncology Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122, Milan, Italy.
Michelino De LaurentiisDepartment of Breast and Thoracic Oncology, Division of Breast Medical Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Pascale, Naples, Italy.
Federica VillaMedical Oncology, Oncology Department ASST Lecco, 23900 Lecco, Italy.
Rossana BerardiDepartment of Medical Oncology, Università Politecnica Delle Marche, AOU delle Marche, Ancona, Italy.
Mauro MinelliUOC Oncologia Azienda Ospedaliera San Giovanni Addolorata, Rome, Italy.
Vittorio AltomareDepartment of Breast Surgery, Fondazione Policlinico Universitario Campus Bio-Medico, Rome,  Italy.
Claudio VernieriDepartment of Oncology and Hemato-Oncology, University of Milan, Milano, Italy.
Giuseppe CuriglianoDepartment of Oncology and Hemato-Oncology, University of Milan, Milano, Italy.ORCID 0000-0003-1781-2518
Bruno VincenziMedical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico Via Alvaro del Portillo 200, Italy.
Giuseppe ToniniMedical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico Via Alvaro del Portillo 200, Italy.
Daniele SantiniDip. Scienze e Biotecnologie Medico-chirurgiche, Policlinico Umberto I, "Sapienza" University of Rome, Rome, Italy.
Francesco PantanoMedical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico Via Alvaro del Portillo 200, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe introduction of CDK4/6 inhibitors (CDK4/6i) has improved outcomes in hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer (mBC), including in patients with bone metastases. Assessing their comparative effectiveness in real-world settings is crucial.

methodsThis retrospective, multicenter cohort study (January 2019-December 2023; median follow-up 39 months) evaluated the real-world progression-free survival (rwPFS) of abemaciclib, ribociclib, and palbociclib combined with endocrine therapy (ET) in HR+/HER2- mBC patients with bone metastases. Overall survival (OS) was a secondary exploratory endpoint. A total of 1399 patients with ECOG PS 0-1 and at least 12 months of follow-up were included. Analyses used propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) to adjust for confounding.

resultsPalbociclib showed shorter rwPFS (22 months) compared to abemaciclib (32 months; HR = 1.47, p = 0.001) and ribociclib (35 months; HR = 1.49, p < 0.001). No significant difference was observed between abemaciclib and ribociclib. OS was also lower with palbociclib (47 months) versus abemaciclib (60 months; HR = 1.77, p < 0.001) and ribociclib (64 months; HR = 1.69, p = 0.001). Results were consistent after PSM and IPTW adjustment.

conclusionRibociclib and abemaciclib may provide superior rwPFS and OS compared to palbociclib in HR+/HER2- mBC patients with bone metastases.

Indexed as

Bone NeoplasmsBreast NeoplasmsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Protein Kinase InhibitorsAdultAgedAminopyridinesBenzimidazolesErb-b2 Receptor Tyrosine KinasesFemaleHumansMiddle AgedPiperazinesProgression-Free SurvivalPurinesabemaciclibAminopyridinesBenzimidazolesCDK4 protein, humanCDK6 protein, humanCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6ERBB2 protein, humanErb-b2 Receptor Tyrosine KinasespalbociclibPiperazinesProtein Kinase InhibitorsPurinesPyridinesReceptors, EstrogenReceptors, Progesteroneribociclibbone metastasesbreast cancerCDK4/6 inhibitors

Identifiers

PMID41992832
PMCPMC13127761

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.